anti met Search Results


90
ATCC atcc pta 7897
Atcc Pta 7897, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/Fab-Met-2+Human+anti/us08039598-246-37-37
Average 90 stars, based on 1 article reviews
atcc pta 7897 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc phosphorylated met
Figure 1 NRG-1b-dependent ErbB-3/Akt activation is inhibited by MP-RM-1. (a) pSuper 4Mut and shErbB-3 infected MDA-MB- 435 and IR-8 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then stimulated with 10 ng/ml of NRG-1b for 5 min before lysis. Cell lysates where then probed with the indicated antibodies. (b) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with 10 mg/ml of MP-RM-1 for the indicated time before NRG-1b stimulation. Cell lysates were immunoblotted for <t>phosphorylated</t> ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. (c) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the indicated amount of MP- RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. <t>Anti-p-ErbB-3</t> and anti-p-Akt immunoreactivity was quantified and plotted after normalization for total ErbB-3 and Akt immunoreactiviy (right panels). (d) IR-8 human melanoma cancer cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the 10 mg/ml of MP-RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control.
Phosphorylated Met, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/Phospho-Met+(Tyr1234%2F1235)+Antibody/pm21822299-158-12-17
Average 95 stars, based on 1 article reviews
phosphorylated met - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc phospho met
Figure 1 NRG-1b-dependent ErbB-3/Akt activation is inhibited by MP-RM-1. (a) pSuper 4Mut and shErbB-3 infected MDA-MB- 435 and IR-8 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then stimulated with 10 ng/ml of NRG-1b for 5 min before lysis. Cell lysates where then probed with the indicated antibodies. (b) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with 10 mg/ml of MP-RM-1 for the indicated time before NRG-1b stimulation. Cell lysates were immunoblotted for <t>phosphorylated</t> ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. (c) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the indicated amount of MP- RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. <t>Anti-p-ErbB-3</t> and anti-p-Akt immunoreactivity was quantified and plotted after normalization for total ErbB-3 and Akt immunoreactiviy (right panels). (d) IR-8 human melanoma cancer cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the 10 mg/ml of MP-RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control.
Phospho Met, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/Phospho-Met+(Tyr1349)+Antibody/10__1074_slash_jbc__m111__333435-52-5-27
Average 94 stars, based on 1 article reviews
phospho met - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc met
Figure 1 NRG-1b-dependent ErbB-3/Akt activation is inhibited by MP-RM-1. (a) pSuper 4Mut and shErbB-3 infected MDA-MB- 435 and IR-8 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then stimulated with 10 ng/ml of NRG-1b for 5 min before lysis. Cell lysates where then probed with the indicated antibodies. (b) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with 10 mg/ml of MP-RM-1 for the indicated time before NRG-1b stimulation. Cell lysates were immunoblotted for <t>phosphorylated</t> ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. (c) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the indicated amount of MP- RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. <t>Anti-p-ErbB-3</t> and anti-p-Akt immunoreactivity was quantified and plotted after normalization for total ErbB-3 and Akt immunoreactiviy (right panels). (d) IR-8 human melanoma cancer cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the 10 mg/ml of MP-RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control.
Met, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/Met+Antibody/pm36428800-90-4-18
Average 96 stars, based on 1 article reviews
met - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Proteintech msra
FIG. 2. Effects of RP on hepatic expression levels of <t>MsrA,</t> <t>MsrB2,</t> and MsrB3 in growing and adult rats. (A) Hepatic protein expression levels and mRNA levels of total MsrA. (B) Nuclear and cytosolic MsrA protein contents. (C) Hepatic protein expression levels and mRNA levels of total MsrB2. (D) Hepatic protein expression levels and mRNA levels of total MsrB3. (E) Nuclear MsrB2 protein contents. (F) Nuclear MsrB3 protein contents. (G) Cytosolic MsrB2 protein levels. (H) Cytosolic MsrB3 protein levels. Values are the means – SEM (n = 6). *P < .05, in comparison with CAS-A. **P < .05, in comparison with CAS-G. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MsrA, methionine sulfoxide reductase A; MsrB2, methionine sulfoxide reductase B2; MsrB3, methionine sulfoxide reductase B3.
Msra, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/MSRA+Antibody/pm32069428-37-40-77
Average 93 stars, based on 1 article reviews
msra - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Proteintech met
FIG. 2. Effects of RP on hepatic expression levels of <t>MsrA,</t> <t>MsrB2,</t> and MsrB3 in growing and adult rats. (A) Hepatic protein expression levels and mRNA levels of total MsrA. (B) Nuclear and cytosolic MsrA protein contents. (C) Hepatic protein expression levels and mRNA levels of total MsrB2. (D) Hepatic protein expression levels and mRNA levels of total MsrB3. (E) Nuclear MsrB2 protein contents. (F) Nuclear MsrB3 protein contents. (G) Cytosolic MsrB2 protein levels. (H) Cytosolic MsrB3 protein levels. Values are the means – SEM (n = 6). *P < .05, in comparison with CAS-A. **P < .05, in comparison with CAS-G. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MsrA, methionine sulfoxide reductase A; MsrB2, methionine sulfoxide reductase B2; MsrB3, methionine sulfoxide reductase B3.
Met, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/GZMM+Antibody/pm39773744-63-23-25
Average 93 stars, based on 1 article reviews
met - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology polyclonal anti met antibody
Figure 6 TGF b2 inhibition of MAPK activation by HGF. (a) HUVEC were treated with 30 ng/ml HGF either in the absence or in the presence of 30 ng/ml TGF b2. Cell extracts were immunoprecipitated with an anti-phosphotyrosine PY20 anti- body and Western blot was performed using a <t>polyclonal</t> antibody against erk-2/p42MAPK. (b) MAPK activity in HUVEC treated with HGF and TGF b2 alone or in combination for 15 min was detected by evaluating the phosphorylation of a speci®c substrate, PHAS-1, as described
Polyclonal Anti Met Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/Met+Antibody/pm10644987-151-9-12
Average 94 stars, based on 1 article reviews
polyclonal anti met antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc phosphorylated c met
Figure 6 TGF b2 inhibition of MAPK activation by HGF. (a) HUVEC were treated with 30 ng/ml HGF either in the absence or in the presence of 30 ng/ml TGF b2. Cell extracts were immunoprecipitated with an anti-phosphotyrosine PY20 anti- body and Western blot was performed using a <t>polyclonal</t> antibody against erk-2/p42MAPK. (b) MAPK activity in HUVEC treated with HGF and TGF b2 alone or in combination for 15 min was detected by evaluating the phosphorylation of a speci®c substrate, PHAS-1, as described
Phosphorylated C Met, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/PhosphoPlus+Met+(Tyr1234%2FTyr1235)+Antibody+Duet/pm36007867-103-48-51
Average 93 stars, based on 1 article reviews
phosphorylated c met - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Proteintech c met
Figure 6 TGF b2 inhibition of MAPK activation by HGF. (a) HUVEC were treated with 30 ng/ml HGF either in the absence or in the presence of 30 ng/ml TGF b2. Cell extracts were immunoprecipitated with an anti-phosphotyrosine PY20 anti- body and Western blot was performed using a <t>polyclonal</t> antibody against erk-2/p42MAPK. (b) MAPK activity in HUVEC treated with HGF and TGF b2 alone or in combination for 15 min was detected by evaluating the phosphorylation of a speci®c substrate, PHAS-1, as described
C Met, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/c-Met+(Cytoplasmic)+Antibody/pm41856115-237-6-8
Average 94 stars, based on 1 article reviews
c met - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
R&D Systems polyclonal c met antibody baf358
Figure 6 TGF b2 inhibition of MAPK activation by HGF. (a) HUVEC were treated with 30 ng/ml HGF either in the absence or in the presence of 30 ng/ml TGF b2. Cell extracts were immunoprecipitated with an anti-phosphotyrosine PY20 anti- body and Western blot was performed using a <t>polyclonal</t> antibody against erk-2/p42MAPK. (b) MAPK activity in HUVEC treated with HGF and TGF b2 alone or in combination for 15 min was detected by evaluating the phosphorylation of a speci®c substrate, PHAS-1, as described
Polyclonal C Met Antibody Baf358, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/Human+HGFR%2Fc-MET+Biotinylated+Antibody/pmc03502238-287-4-8
Average 92 stars, based on 1 article reviews
polyclonal c met antibody baf358 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
R&D Systems antimet
Figure 6 TGF b2 inhibition of MAPK activation by HGF. (a) HUVEC were treated with 30 ng/ml HGF either in the absence or in the presence of 30 ng/ml TGF b2. Cell extracts were immunoprecipitated with an anti-phosphotyrosine PY20 anti- body and Western blot was performed using a <t>polyclonal</t> antibody against erk-2/p42MAPK. (b) MAPK activity in HUVEC treated with HGF and TGF b2 alone or in combination for 15 min was detected by evaluating the phosphorylation of a speci®c substrate, PHAS-1, as described
Antimet, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/Human+HGFR%2Fc-MET+Antibody/10__1186_slash_s12645___024___00267___1-156-6-39
Average 93 stars, based on 1 article reviews
antimet - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
R&D Systems rb igg abcam 8f11 ms igm r d systems polyclonal
Figure 6 TGF b2 inhibition of MAPK activation by HGF. (a) HUVEC were treated with 30 ng/ml HGF either in the absence or in the presence of 30 ng/ml TGF b2. Cell extracts were immunoprecipitated with an anti-phosphotyrosine PY20 anti- body and Western blot was performed using a <t>polyclonal</t> antibody against erk-2/p42MAPK. (b) MAPK activity in HUVEC treated with HGF and TGF b2 alone or in combination for 15 min was detected by evaluating the phosphorylation of a speci®c substrate, PHAS-1, as described
Rb Igg Abcam 8f11 Ms Igm R D Systems Polyclonal, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+met/Human+HGFR%2Fc-MET+Antibody/10__1038_slash_labinvest__2014__38-857-42-48
Average 94 stars, based on 1 article reviews
rb igg abcam 8f11 ms igm r d systems polyclonal - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Figure 1 NRG-1b-dependent ErbB-3/Akt activation is inhibited by MP-RM-1. (a) pSuper 4Mut and shErbB-3 infected MDA-MB- 435 and IR-8 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then stimulated with 10 ng/ml of NRG-1b for 5 min before lysis. Cell lysates where then probed with the indicated antibodies. (b) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with 10 mg/ml of MP-RM-1 for the indicated time before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. (c) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the indicated amount of MP- RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. Anti-p-ErbB-3 and anti-p-Akt immunoreactivity was quantified and plotted after normalization for total ErbB-3 and Akt immunoreactiviy (right panels). (d) IR-8 human melanoma cancer cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the 10 mg/ml of MP-RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control.

Journal: Oncogene

Article Title: An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.

doi: 10.1038/onc.2011.322

Figure Lengend Snippet: Figure 1 NRG-1b-dependent ErbB-3/Akt activation is inhibited by MP-RM-1. (a) pSuper 4Mut and shErbB-3 infected MDA-MB- 435 and IR-8 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then stimulated with 10 ng/ml of NRG-1b for 5 min before lysis. Cell lysates where then probed with the indicated antibodies. (b) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with 10 mg/ml of MP-RM-1 for the indicated time before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. (c) MDA-MB-435 cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the indicated amount of MP- RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control. Anti-p-ErbB-3 and anti-p-Akt immunoreactivity was quantified and plotted after normalization for total ErbB-3 and Akt immunoreactiviy (right panels). (d) IR-8 human melanoma cancer cells were grown in 0.2% FBS RPMI 1640 for 24 h and then incubated with the 10 mg/ml of MP-RM-1 for 2 h before NRG-1b stimulation. Cell lysates were immunoblotted for phosphorylated ErbB-3 and Akt expression levels. The same filter was reprobed with anti-ErbB-3 and anti-Akt antibodies for a loading control.

Article Snippet: Antibodies were as follows: phosphorylated ErbB-3 (Tyr1289), phosphorylated Akt (Ser473), Akt, PLCg1, phosphorylated MET (Tyr1234 1235) from Cell Signaling (Boston, MA, USA); C-17 ErbB-3 and MET from Santa Cruz Biotechnology (Santa Cruz, CA, USA); Actin from Sigma-Aldrich (St Louis, MO, USA); anti-ErbB-2 antibody 300G9 was obtained as described in Digiesi et al. (1992) rhodamine[125I]-labeled phalloidin from Sigma; Draq5 from Alexis; Yo-Pro dye from Invitrogen (Carlsbad, CA, USA).

Techniques: Activation Assay, Infection, Lysis, Incubation, Expressing, Control

Figure 5 MP-RM-1inhibits ligand-indipendent activation of ErbB-3. (a) pSuper 4Mut and shErbB-3 infected MKN-45 cancer cells were grown in serum-free DMEM for 24 h and then lysed for immunoblot analysis. (b) MKN-45 cells were grown in serum-free DMEM for 24 h and then exposed to MP-RM-1 for the indicated time. Lysates were analyzed by immunoblot for phosphorylated ErbB-3 and phosphorylated Akt. The same filter was reprobed with the indicated antibodies for a loading control. (c) MKN-45 cells were grown in serum free DMEM for 24 h and then incubated for 2 h with trastuzumab (10 mg/ml), MP-RM-1 (10 mg/ml) or increasing amount of MET inhibitor SU11274. Lysates were analyzed by immunoblot with the indicated antibodies. (d) MKN-45 cells were grown in serum-free DMEM for 24 h and then incubated with 10 mg/ml of MP-RM-1 for 15 and 120 min. Lysates were analysed by immunoblot with the indicated antibodies (lower panel) or immunoprecipitated with an anti-phosphorylated MET antibody and then probed with an anti-ErbB-3 antibody (upper panel). (e) MKN-45 cells were grown in serum free DMEM for 24 h and then incubated with 1 mg/ml of SU1174 alone or together with 10 mg/ml of MP-RM-1. After 2 h, NRG-1b (10 ng/ml) was added, as indicated.

Journal: Oncogene

Article Title: An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.

doi: 10.1038/onc.2011.322

Figure Lengend Snippet: Figure 5 MP-RM-1inhibits ligand-indipendent activation of ErbB-3. (a) pSuper 4Mut and shErbB-3 infected MKN-45 cancer cells were grown in serum-free DMEM for 24 h and then lysed for immunoblot analysis. (b) MKN-45 cells were grown in serum-free DMEM for 24 h and then exposed to MP-RM-1 for the indicated time. Lysates were analyzed by immunoblot for phosphorylated ErbB-3 and phosphorylated Akt. The same filter was reprobed with the indicated antibodies for a loading control. (c) MKN-45 cells were grown in serum free DMEM for 24 h and then incubated for 2 h with trastuzumab (10 mg/ml), MP-RM-1 (10 mg/ml) or increasing amount of MET inhibitor SU11274. Lysates were analyzed by immunoblot with the indicated antibodies. (d) MKN-45 cells were grown in serum-free DMEM for 24 h and then incubated with 10 mg/ml of MP-RM-1 for 15 and 120 min. Lysates were analysed by immunoblot with the indicated antibodies (lower panel) or immunoprecipitated with an anti-phosphorylated MET antibody and then probed with an anti-ErbB-3 antibody (upper panel). (e) MKN-45 cells were grown in serum free DMEM for 24 h and then incubated with 1 mg/ml of SU1174 alone or together with 10 mg/ml of MP-RM-1. After 2 h, NRG-1b (10 ng/ml) was added, as indicated.

Article Snippet: Antibodies were as follows: phosphorylated ErbB-3 (Tyr1289), phosphorylated Akt (Ser473), Akt, PLCg1, phosphorylated MET (Tyr1234 1235) from Cell Signaling (Boston, MA, USA); C-17 ErbB-3 and MET from Santa Cruz Biotechnology (Santa Cruz, CA, USA); Actin from Sigma-Aldrich (St Louis, MO, USA); anti-ErbB-2 antibody 300G9 was obtained as described in Digiesi et al. (1992) rhodamine[125I]-labeled phalloidin from Sigma; Draq5 from Alexis; Yo-Pro dye from Invitrogen (Carlsbad, CA, USA).

Techniques: Activation Assay, Infection, Western Blot, Control, Incubation, Immunoprecipitation

FIG. 2. Effects of RP on hepatic expression levels of MsrA, MsrB2, and MsrB3 in growing and adult rats. (A) Hepatic protein expression levels and mRNA levels of total MsrA. (B) Nuclear and cytosolic MsrA protein contents. (C) Hepatic protein expression levels and mRNA levels of total MsrB2. (D) Hepatic protein expression levels and mRNA levels of total MsrB3. (E) Nuclear MsrB2 protein contents. (F) Nuclear MsrB3 protein contents. (G) Cytosolic MsrB2 protein levels. (H) Cytosolic MsrB3 protein levels. Values are the means – SEM (n = 6). *P < .05, in comparison with CAS-A. **P < .05, in comparison with CAS-G. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MsrA, methionine sulfoxide reductase A; MsrB2, methionine sulfoxide reductase B2; MsrB3, methionine sulfoxide reductase B3.

Journal: Journal of medicinal food

Article Title: Rice Protein Exerts Endogenous Antioxidant Capacity via Methionine Sulfoxide Reductase and the Nrf2 Antioxidant System Independent of Age.

doi: 10.1089/jmf.2019.4504

Figure Lengend Snippet: FIG. 2. Effects of RP on hepatic expression levels of MsrA, MsrB2, and MsrB3 in growing and adult rats. (A) Hepatic protein expression levels and mRNA levels of total MsrA. (B) Nuclear and cytosolic MsrA protein contents. (C) Hepatic protein expression levels and mRNA levels of total MsrB2. (D) Hepatic protein expression levels and mRNA levels of total MsrB3. (E) Nuclear MsrB2 protein contents. (F) Nuclear MsrB3 protein contents. (G) Cytosolic MsrB2 protein levels. (H) Cytosolic MsrB3 protein levels. Values are the means – SEM (n = 6). *P < .05, in comparison with CAS-A. **P < .05, in comparison with CAS-G. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MsrA, methionine sulfoxide reductase A; MsrB2, methionine sulfoxide reductase B2; MsrB3, methionine sulfoxide reductase B3.

Article Snippet: Protein extraction and Western blotting analysis The total, cytoplasmic, and nuclear proteins were used for Western blot analysis, which were prepared as described in our previous studies.16,22,23,28 The primary antibodies of Nrf2, Kelch-like ECH-associated protein 1 (Keap1), Cullin 3 (Cul3), MsrA, MsrB2, MsrB3, glutamate cysteine ligase catalytic subunit (GCLC), glutamate cysteine ligase modulatory subunit (GCLM), glutathione synthase (GS), GR, GSTA1, SOD, CAT, heme oxygenase 1 (HO-1), NAD(P)H: quinone oxidoreductase 1 (NQO1), H1.2, and GAPDH were purchased from Proteintech (Wuhan, China), and methionine adenosyltransferase Ia (MAT1A), S-adenosylhomocysteine hydrolase (SAHH), cystathionine b-synthase (CBS), cystathionine c-lyse (CTH), GPx1/2, and second antibody were Table 1.

Techniques: Expressing, Comparison

Figure 6 TGF b2 inhibition of MAPK activation by HGF. (a) HUVEC were treated with 30 ng/ml HGF either in the absence or in the presence of 30 ng/ml TGF b2. Cell extracts were immunoprecipitated with an anti-phosphotyrosine PY20 anti- body and Western blot was performed using a polyclonal antibody against erk-2/p42MAPK. (b) MAPK activity in HUVEC treated with HGF and TGF b2 alone or in combination for 15 min was detected by evaluating the phosphorylation of a speci®c substrate, PHAS-1, as described

Journal: Oncogene

Article Title: Transforming growth factor beta2 inhibition of hepatocyte growth factor-induced endothelial proliferation and migration.

doi: 10.1038/sj.onc.1203225

Figure Lengend Snippet: Figure 6 TGF b2 inhibition of MAPK activation by HGF. (a) HUVEC were treated with 30 ng/ml HGF either in the absence or in the presence of 30 ng/ml TGF b2. Cell extracts were immunoprecipitated with an anti-phosphotyrosine PY20 anti- body and Western blot was performed using a polyclonal antibody against erk-2/p42MAPK. (b) MAPK activity in HUVEC treated with HGF and TGF b2 alone or in combination for 15 min was detected by evaluating the phosphorylation of a speci®c substrate, PHAS-1, as described

Article Snippet: The blot was then stripped and incubated with a polyclonal anti-Met antibody (Santa Cruz) (Maier et al., 1996).

Techniques: Inhibition, Activation Assay, Immunoprecipitation, Western Blot, Activity Assay, Phospho-proteomics